WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201250
Description: Eniluracil, also known as GW776 and GW776C85, is an orally active and irreversible inhibitor of dihydropyrimidine dehydrogenase. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
MedKoo Cat#: 201250
Chemical Formula: C6H4N2O2
Exact Mass: 136.02728
Molecular Weight: 136.11
Elemental Analysis: C, 52.95; H, 2.96; N, 20.58; O, 23.51
Synonym: 776C85; DH300004; GW776; GW-776; GW 776; GW-776C85; GW 776C85; GW776C85; NSC 687296; 5-ethynyluracil; ethynyluracil.
IUPAC/Chemical Name: 5-ethynylpyrimidine-2,4(1H,3H)-dione.
InChi Key: JOZGNYDSEBIJDH-UHFFFAOYSA-N
InChi Code: InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10)
SMILES Code: O=C1NC(C(C#C)=CN1)=O
Eniluracil plus 5‑FU was previously being developed by GlaxoSmithKline (GSK). Although the therapy was successful in Phase I and Phase II clinical trials, it tended to produce less antitumor activity than the control therapy in two Phase III trials. Development was subsequently stopped. Since then, Adherex has learned that with the dose and schedule used in the previous GSK Phase III trials may not have been optimal. Preclinical studies have shown that when eniluracil is present in high ratios to 5‑FU, it decreases the antitumor activity. In the Phase III trials, the eniluracil:5‑FU ratio was 10:1. see: http://adherex.com/product-candidate/eniluracil-clinical-development/
Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (uracil reductase), the enzyme that rapidly catabolizes 5-fluorouracil (5-FU). Although eniluracil in combination with 5-FU was promising in phase I and II studies, in 2 multicenter phase III colorectal cancer studies, eniluracil dosed in a 10-to-1 ratio to 5-FU produced less antitumor benefit than the std. regimen of 5-FU/leucovorin without eniluracil. Clinical Colorectal Cancer (2010), 9(1), 52-54.